What is the teduglutide dose, and how is the vial mixed?

Every vial at a glance.

Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
Vial0.5 mL of water
5 mg10 mg/mL: 2,000 mcg is 20 units, 3,000 mcg is 30 units, 3,600 mcg is 36 units

The US label gives 0.05 mg/kg once daily by subcutaneous injection for adults and children 1 year of age and older with short bowel syndrome who are dependent on parenteral support, from a 5 mg vial mixed with 0.5 mL of water to 10 mg/mL.1

What the kit holds

The US label supplies 5 mg of teduglutide powder in a single-dose vial, with 0.5 mL Sterile Water for Injection in a prefilled syringe.1 A one-vial kit also holds a separate needle, a 1 mL dosing syringe and four alcohol swabs, and kits are dispensed as one vial or 30 vials.1 The EU product information adds a 1.25 mg vial that gives 2.5 mg/ml in 0.5 ml, for paediatric patients under 20 kg and those aged 4 months to less than 12 months.2 The table's rows come to 0.20 ml, 0.30 ml and 0.36 ml, the EU product information's adult volumes at 38-41 kg, 58-61 kg and 70-73 kg.2

Mixing a 5 mg vial and reading the syringe

The US label says to mix each vial with the 0.5 mL of preservative-free Sterile Water for Injection in the prefilled syringe, giving 10 mg/mL.1 It says not to shake the vial, and not to use a product that stays undissolved after a second attempt.1

3,000 mcg of Teduglutide (GLP-2) from a 5 mg vial mixed with 0.5 mL is 30 units on a U-100 syringe.

Worked example: 3 mg from a 5 mg vial mixed with 0.5 mL is 0.30 mL, or 30 units on a U-100 syringe; 0.30 ml is the EU product information's adult volume at 58-61 kg.2

3,000 mcg of Teduglutide (GLP-2) from a 5 mg vial mixed with 0.5 mL is 30 units on a U-100 syringe.

Dose by weight and what trials used

The US label gives 0.05 mg/kg once daily by subcutaneous injection for adults and pediatric patients 1 year of age and older with short bowel syndrome who are dependent on parenteral support.1 The EU product information gives 0.05 mg/kg body weight once daily for adults with short bowel syndrome who are stable following a period of intestinal adaptation, sets the number of vials by body weight and has the physician weigh the patient each visit.2 Its adult volume table for the 5 mg vial runs from 0.20 ml at 38-41 kg to 0.46 ml at 90-93 kg, with 0.30 ml at 58-61 kg.2

In the Jeppesen trial of 83 patients over 24 weeks, 0.05 mg/kg/day had a significant effect on the graded response score (16/35, p=0.007) and 0.10 mg/kg/day did not (8/32 vs 1/16, p=0.16), against placebo.3

TrialDose and schedulePeopleLength
Jeppesen trial30.10 mg/kg/day, 0.05 mg/kg/day or placebo, once daily83 patients (n=32, 35, 16); the US label gives n=33 on 0.1 mg/kg/day124 weeks
STEPS, Jeppesen 201240.05 mg/kg/d or placebo, once daily86 patients (n=43 per arm)524 weeks
Chiba paediatric studies6Open-label 0.05 mg/kg/day; infants in one study randomised to teduglutide or standard of careTwelve infants and 8 children24 weeks, plus a 24-week extension

Milligram has no logged share for teduglutide that can be shown.

Storage before and after mixing

The US label says one-vial kits and the vials for 30-vial kits are stored refrigerated at 2°C to 8°C before dispensing, then at room temperature up to 25°C with a 90-day "use by" dating after dispensing, and not frozen.1 The EU product information says to store the 1.25 mg vial in a refrigerator (2 °C – 8 °C) and the 5 mg vial below 25 °C, neither frozen, with a shelf life of 4 years unopened.2 Once mixed, it says to administer within 3 hours, discard the unused portion, and not shake or freeze the solution.1 The EU product information shows stability for 3 hours at 25 °C for the 5 mg vial and 24 hours up to 25 °C for the 1.25 mg vial, and for both normally not over 24 hours at 2 to 8 °C, unless reconstitution has taken place in controlled and validated aseptic conditions.2 The two texts do not agree on how long a mixed vial keeps.

Frequently asked questions

How much can be drawn from a mixed vial?

The US label says at most 0.38 mL (3.8 mg) can be withdrawn from a reconstituted vial for dosing.1 The EU product information's adult table goes above that, to 0.46 ml at 90-93 kg.2

Where is teduglutide injected?

The US label says subcutaneous use only, alternating between the 4 quadrants of the abdomen, or alternating thighs or arms.1

Is the dose different with kidney problems?

The US label gives 0.025 mg/kg once daily for adults and children with moderate or severe renal impairment or end-stage renal disease (estimated glomerular filtration rate less than 60 mL/min/1.73 m2).1 The EU product information says the daily dose is to be reduced by 50% in adult or paediatric patients with moderate and severe renal impairment (creatinine clearance less than 50 ml/min) and end-stage renal disease.2

Are there cycles?

Neither the US label nor the EU product information gives an on/off cycle for adults. The EU product information evaluates the effect after 6 months in adults, and in children after 6 months, or 12 weeks below the age of two years; it describes infant extension studies of up to 9 cycles of 24 weeks.2

References

  1. Takeda (DailyMed). These highlights do not include all the information needed to use GATTEX safely and effectively. See full prescribing information for GATTEX. GATTEX ® (teduglutide) for injection, for subcutaneous use Initial U.S. Approval: 2012. 2025. dailymed.nlm.nih.gov
  2. EMA. Revestive, INN-teduglutide. ema.europa.eu
  3. PMC. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. 2011. pmc.ncbi.nlm.nih.gov
  4. PubMed. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. 2012. pubmed.ncbi.nlm.nih.gov
  5. ClinicalTrials.gov. NCT00798967: Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects. 2012. clinicaltrials.gov
  6. PMC. Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support. 2023. pmc.ncbi.nlm.nih.gov